StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN)

Research analysts at StockNews.com started coverage on shares of OpGen (NASDAQ:OPGN) in a note issued to investors on Wednesday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Down 13.4 %

Shares of NASDAQ OPGN opened at $0.94 on Wednesday. OpGen has a 52 week low of $0.53 and a 52 week high of $9.90. The firm’s fifty day moving average is $1.05 and its 200 day moving average is $1.68.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.